A phase II trial of split, low-dose docetaxel and low-dose capecitabine: A tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer

Clinical Breast Cancer

Volumn 8, Issue 2, 2008, Pages 162-167

  Silva, Orlando ^a   Lopes, Gilberto ^b   Morgenzstern, Daniel ^c   Lobo, Christopher ^d   Doliny, Philomena ^a   Santos, Edgardo ^e   Abdullah, Sakher ^f   Gautam, Umang ^g   Reis, Isildinha ^a   Welsh, Catherine ^a   Slingerland, Joyce ^a   Hurley, Judith ^a   Gluck, Stefan ^a  

^a UNIVERSITY OF MIAMI   (United States)

^b Johns Hopkins Singapore   (Singapore)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Florida Cancer Specialists Research Institute   (United States)

^e TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^g Hematology Oncology   (United States)

Author keywords

Anemia; Bone metastasis; Thymidine phosphorylase; Time to treatment failure

Indexed keywords

CAPECITABINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE METASTASIS; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; EDEMA; ENTHESOPATHY; EPIPHORA; FATIGUE; FEMALE; GASTROESOPHAGEAL REFLUX; HAND FOOT SYNDROME; HEADACHE; HUMAN; INFECTION; LEUKOPENIA; LIVER METASTASIS; LOW DRUG DOSE; LUNG METASTASIS; LYMPH NODE METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; RASH; SIDE EFFECT; SKIN METASTASIS; STOMACH PERFORATION; THROMBOCYTOPENIA;

EID: 43249115614     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2008.n.017     Document Type: Article

References (12)

1. J O'Shaughnessy D Miles S Vukelja Superior survival with capecitabine plus docetaxel combination therapy in anthracyclinepretreated patients with advanced breast cancer: phase III trial results J Clin Oncol 20 2002 2812 2823
2. R Leonard J O'Shaughnessy S Vukelja Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage? Ann Oncol 17 2006 1379 1385
3. S Beslija N Obralic H Basic Randomized trial of sequence vs. combination of capecitabine (X) and docetaxel (T): XT vs. T followed by X after progression as first-line therapy for patients (pts) with metastatic breast cancer (MBC) J Clin Oncol 24 18 suppl 2006 20s (Abstract 571).
4. K Fujimoto-Ouchi Y Tanaka T Tominaga Schedule dependency of antitumor activity in combination therapy with capecitabine/5′-deoxy-5-fluorouridine and docetaxel in breast cancer models Clin Cancer Res 7 2001 1079 1086
5. N Sawada T Ishikawa Y Fukase Induction of thymidine-phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenographs Clin Cancer Res 4 1998 1013 1019
6. RK Ramanathan S Ramalingam MJ Egorin Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies Cancer Chemother Pharmacol 55 2005 354 360
7. P Nadella C Shapiro GA Otterson Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies J Clin Oncol 20 2002 2616 2623
8. P Therasse SG Arbuck EA Eisenhauer New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 2000 205 216
9. Common Terminology Criteria for Adverse Events Index. Version 3.0. National Institutes of Health. National Cancer Institute Available at: http://ctep.cancer.gov/forms/CTCAE_Index.pdf
10. JR Mackey KS Tonkin SL Koski Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer Clin Breast Cancer 5 2004 287 292
11. E Mrozek B Ramaswamy D Young Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer Clin Breast Cancer 7 2006 141 145
12. V Harvey H Mouridsen V Semiglazov Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer J Clin Oncol 24 2006 4963 4970